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ABSTRACT
Large-cell neuroendocrine tumors (NETs) are poorly differentiated malignancies of rare incidence and aggressive nature. 
NETs mostly arise in the lung followed by the gastrointestinal tract, although they are potentially ubiquitous throughout the 
body. Primary unknown NET has a worse prognosis and shorter survival comparing with other NETs, with limited available 
data in the literature concerning this subgroup. The authors report the case of large-cell NET with supraclavicular lymph 
node presentation. Total excisional biopsy revealed an enlarged adenopathy 18 × 15 × 10 mm, which was extensively 
infiltrated by a solid malignant neoplasm composed of large cells with granular chromatin, nuclear pseudo-inclusions, high 
mitotic index, and focal necrosis, with a Ki 67 index 25-30% and positive immunohistochemical study for the expression 
of cytokeratin 8/18, chromogranin, synaptophysin, and thyroid transcriptional factor-1 (TTF-1). There was no evidence of 
primary location apart from two infracentimetric lung lesions that could not be accessed for biopsy and were negative at 
both somatostatin receptor scintigraphy and positron emission tomography. The NET relapsed with three mediastinal masses, 
so the patient was started on chemotherapy with carboplatin and etoposide with initial total response. Early progression 
showed no response to further chemotherapy regimens (temozolomide, oral etoposide); therefore, the patient was treated 
with local radiotherapy. This patient has an atypical long survival (54 months) compared to the literature data. In fact, there 
are few long-term survivors of large-cell NET and they are all related to complete surgical resection. 
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INTRODUCTION
Neuroendocrine tumors (NETs) constitute a 
heterogeneous group of malignancies. These rare 
neoplasms emerge yearly with four to five new 
cases/100,000 inhabitants in the United States, 
according to the National Cancer Institute’s Surveillance, 
Epidemiology, and End Results (SEER) database 
between 2000 and 2004.1 The recent increasing 
incidence is partially justified by advances in diagnostic 
methods, such as immunohistochemistry and imaging.
NETs are grouped into well-differentiated tumors 
or poorly-differentiated carcinomas, based on the 
morphology and markers of proliferation (including 
Ki-67 and mitotic index), with distinct clinical behavior 
and prognosis.2-4 Poorly differentiated NETs (including 
both small and large cells), tend to be aggressive and 
grow rapidly. In contrast, well-differentiated NETs are 
indolent with a more favorable prognosis.5
The majority of NETs arise in the lung, followed by 
the gastrointestinal tract (most commonly in the lower 
digestive tract). Nevertheless, NETs are ubiquitous 
throughout the body.6-9 The unknown primary NET 
emerges from an occult or clinically undetectable 
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primary site in several possible locations, such as 
bronchus, pancreas, gastric, colon, rectum and other 
sites.5 This subset of patients is the one with worse 
prognosis and shorter survival.6
CASE REPORT
A 75-year-old female, non-smoker, presented 
with a painless 16 mm adenopathy at the right 
supraclavicular area, with no other relevant findings 
at physical examination and laboratory tests. Cytology 
from a fine-needle biopsy revealed non-small-cell 
carcinoma with neuroendocrine differentiation 
(Figure 1).
The neck-chest-abdominal-pelvic computed 
tomography (CT) scan showed a unilateral right 
supraclavicular adenopathy measuring 16 mm in 
short axis, with no other suspicious lymph node 
involvement. Only two infracentimetric lung lesions 
(largest 4 mm) at the right inferior lobe were visible, 
with no other suspicious lesions/masses. Somatostatin 
receptor scintigraphy (SSRS) was negative, and no 
other relevant findings in further investigations was 
found (extensive laboratory workup along with upper 
and lower endoscopies and gynecological evaluation).
A total excis ional biopsy was performed, 
and pathologic examination revealed an enlarged 
supraclavicular lymph node (18 × 15 × 10 mm), 
which was extensively infiltrated by a solid malignant 
neoplasm composed of large cells with granular 
chromatin, nuclear pseudo-inclusions, high mitotic 
index (˃20 mitotic figures per 10 high-power field), and 
Figure 1. Fine-needle aspiration of the lymph node. A and B show the presence of large cells with anisokaryosis and 
pseudoinclusions (H&E 200X and 400X respectively); C and D show positivity for CD56 and TTF-1 immunostainings 
respectively (400X each).
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focal necrosis. Immunohistochemical study was positive 
for cytokeratin 8/18, chromogranin, synaptophysin, 
and TTF1, in the absence of calcitonin, thyroglobulin, 
estrogen and progesterone receptors, mammaglobin, 
and S100 protein expression. Ki 67 index was 25-30%. 
This suggested metastatic lymph node involvement from 
non-small neuroendocrine carcinoma of unknown origin 
(possibly pulmonary) (Figure 2).
A CT body scan re-staging showed one persistent 
infracentimetric lesion at the right inferior lobe of 
the lung, which could not be accessed for biopsy. 
Functional imaging with 18F-fluorodeoxyglucose 
positron emission tomography (18F-FDG PET) scan 
demonstrated three foci of intense uptake in the 
mediastinal lymph nodes: particularly in the projection of 
stations 3a (pre-vascular), 4L (left inferior para-tracheal), 
and 10L (left hilar), measuring 25-27 mm. Serum 
chromogranin A was normal.
The patient was treated with carboplatin AUC4 
(day 1) and etoposide 80 mg/m2 (days 1 and 2) every 
21 days. Adjustments to the standard chemotherapy 
protocol (carboplatin instead of cisplatin, dose 
reduction and 2 days’ etoposide) were prescribed 
considering patient’s age and comorbidities. Treatment 
was reasonably tolerated, and the patient presented 
asthenia grade 2 and total alopecia. After 6 cycles, 
the total metabolic response was achieved with an 
entirely negative 18F-FDG PET scan. Chemotherapy 
was then withdrawn and the oncologic surveillance 
was maintained.
Figure 2. Histologic section of the tumor. A and B show the lymph node totally infiltrated by a solid neoplasm. 
Note the presence of neoplasia beyond the node’s capsule within the adjacent soft tissue (H&E 40X). The neoplastic 
cells show an epithelioid phenotype with overlapping features to those of the cytological sample; C, D, E and F 
show immunoexpression of CK8/18, chromogranin, TTF1 and synaptophysin respectively (400X).
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Two months later, the patient start experiencing 
persistent dry cough, dysphonia, fatigue, and exertional 
dyspnea. Reassessment with an 18F-FDG PET scan 
suggested thoracic lymph node relapse with moderate 
18F-FDG uptake; the CT chest scan confirmed disease 
progression of two mediastinal masses of 43 mm in 
station 3a and 33 mm in station 4L. At this stage, 
SSRS revealed high uptake in both mediastinal masses 
(Figure 3).
The patient was treated with lanreotide 120 mg 
subcutaneously every 28 days, with partial clinical 
improvement except for a persistent cough. After the 
sixth cycle, a CT body scan showed indolent disease 
progression with slow mediastinal mass enlargement 
and new confluent lymph nodes. Also, there was a slow 
rising of serum neuron-specific enolase (NSE). Since the 
disease was presenting an atypical slow-progressing 
course, a new biopsy was performed to guide the better 
therapeutic option. Therefore, the patient underwent 
an endobronchial ultrasound-guided transbronchial 
fine-needle aspiration biopsy, which confirmed the 
neuroendocrine carcinoma with similar morphologic 
characteristics of the initial biopsy.
The patient was submitted to an off-label 
chemotherapy with temozolomide 150 mg/m2, 
days 1-5, every 28 days. However, an early disease 
progression was verified after two cycles, with 
enlargement of the mediastinal masses.
Figure 3. Somatostatin receptor scintigraphy revealed a high uptake in two mediastinal masses, consistent with 
disease relapse. A and B show axial and coronal planes of mediastinal mass in 3a station respectively; C and D show 
axial and coronal planes of mediastinal mass in 4L station respectively.
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The  pat ient  was  t reated  wi th  s tandard 
chemotherapy with oral etoposide 150 mg/m2 
(days 1-3), every 21 days. No clinical nor radiologic 
improvement was achieved after the third cycle of 
treatment, with a persistent cough (non-responsive 
to medication) and enlargement of both mediastinal 
masses, although not meeting RECIST 1.1 criteria for 
progressive disease (Figure 4).
Currently, our patient is receiving local treatment 
with external radiotherapy by 3D conformal technique, 
with 6 MV photon energy at a 2.5 Gy daily dose, over 
16 planned fractions up to a 40 Gy total dose aim. 
The patient preserves reasonable performance status 
(punctuating 70% at Karnofsky scale and 1 on the 
Eastern Co-operative Oncology Group scale).
DISCUSSION
Suspicion remains in the face of poor clinical 
evidence for the primary location of our patient’s 
large-cell NET, which presented as supraclavicular 
adenopathy and later relapsed as mediastinal masses. 
Based on epidemiological evidence, we suspect the 
primary site was likely mediastinal or pulmonary.
In the literature, a similar case is reported as 
large-cell NET, which initially presented as an axillary 
lymph node, but the pulmonary origin was verified.10 
In fact, poorly differentiated large-cell NET cases are 
reported to involve multiple metastatic sites (including 
liver, bone, mandibular, skin, mediastinum, and 
retroperitoneum lymph nodes), but a primary origin is 
always confirmed.11-15 There are no cases reported as 
truthfully primary unknown large-cell NET.
Despite the diverse presentation, large-cell 
NET has biological aggressive behavior, enhanced 
chemotherapy sensitivity and short survival.5 Gender 
(female) and age (< 80 years) were the favorable 
survival outcome predictors found in our patient. 
In contrast, the primary unknown site and the poorly 
differentiated grade were negative predictors for a 
better outcome.16
Figure 4. Computed tomography scan showing mediastinal masses enlargement during chemotherapy. A and B show 
axial planes of mediastinal mass in 3a station before and after oral etoposide respectively; C and D show axial planes 
of mediastinal mass in 4L station before and after of oral etoposide respectively.
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How to identify predictors of response and survival 
is still an unsolved question that some studies are 
engaged to answer.17,18 A relevant predictor of response 
to treatment is the Ki 67 index, and the cut-off value 
for a better therapeutic response is 55%. Another 
powerful predictor of survival is the performance 
status, so patients with good performance status had 
a lower percentage of immediate disease progression 
and a higher percentage of longer survival.17 Similarly, 
high values of SUVmax in the 18F-FDG PET may be a 
predictor of response to treatment or survival in poorly 
differentiated NET, although not fully clarified.
In the case presented herein, the first-line 
treatment choice was platinum-based chemotherapy 
with dose adjustments, considering the patient’s age 
and comorbidities.19-21 Despite a total response, the 
patient’s disease-free survival (5 months) was shorter 
when compared to series described in the literature 
regarding gastroenteropancreatic poorly differentiated 
NETs. In 1991, Moertel et al.19 reported 11 months 
of the median interval to progression in 18 patients 
with anaplastic NETs (entity analogous to the current 
extrapulmonary poorly differentiated NETs) treated 
with cisplatin 45 mg/m2 on day 1 and etoposide 
130 mg/m2 for 3 days. Later, Mitry et al.20 reported 
median progression-free survival of 8.9 months in 
41 patients with extrapulmonary poorly differentiated 
NET treated with cisplatin 100 mg/m2 on day 1, and 
etoposide 100 mg/m2 for 3 days. Most recent series 
and studies tend to be exclusively about NET of 
gastrointestinal origin.
After the consensual first-line therapy, there is 
no established second-line for poorly differentiated 
NET based on treatment guidelines.22,23 The choice of 
a somatostatin analogue with proven antiproliferative 
activity as second-line therapy was based on the new 
result of SSRS (positive at relapse) in a patient who was 
not willing to undergo further chemotherapy regimens. 
Lanreotide succeeded in controlling the symptoms; 
however, disease-free survival was shorter than 
that described in the literature.24 After progression, 
well-tolerated and expected effective chemotherapy 
regimens were chosen: temozolomide and oral 
etoposide. There are few case reports in the literature 
that suggest the effectiveness of temozolomide, 
and it is recommended by experts on treatment 
guidelines.22,25,26 Oral etoposide efficacy data remain in 
studies with intravenous etoposide and it was inferred 
in neuroendocrine treatment for this patient with few 
available therapy options.
The contrast  i s  not iceab le  between the 
clinical behavior at disease presentation and at 
recurrence and progression in this particular case. 
Initially, the disease presented with aggressive 
behavior: high uptake of 18F-FDG PET, negative 
SSR, responsive to platinum-based chemotherapy 
and short progression-free survival. Later at relapse 
and subsequent progressions, the disease appeared 
to be more indolent with the novel uptake of SSR; 
it progressed slowly and there was no significant 
response to further treatments. This evolution may 
be due to tumor heterogeneity with different clonal 
cell selection and survival induced by the treatment.
Our patient’s overall survival has been unexpectedly 
long (54 months to date) in contrast with the literature. 
According to the recent SEER database analysis, 
median survival for high-grade NETs is 2.5 months 
for cases of unknown primary origin; 7.6 months for 
pulmonary and 14.5 months for extrapulmonary.6 
Long-term survivors of large-cell NET are few, and all 
cases are related to complete surgical resection.27,28 
Nevertheless, multimodal treatment, including surgery, 
chemotherapy and radiation therapy, can also achieve 
a good response and lead to long survival, even in 
inoperable cases.29
We believe that multimodal treatment has been 
beneficial for our patient. Host immunity factors also 
may have contributed to our patient’s atypically long 
survival, as well as other unclear disease’s features 
that an autopsy may help to clarify at the proper time.
The patient’s approval to report the clinical case 
was given as signed informed consent.
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